Last reviewed · How we verify
Oxaliplatin;Capecitabine
Oxaliplatin and capecitabine work together as a chemotherapy combination: oxaliplatin cross-links DNA to prevent replication, while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.
Oxaliplatin and capecitabine work together as a chemotherapy combination: oxaliplatin cross-links DNA to prevent replication, while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis. Used for Metastatic colorectal cancer, Gastric cancer, Pancreatic cancer.
At a glance
| Generic name | Oxaliplatin;Capecitabine |
|---|---|
| Also known as | Oxaliplatin plus capecitabine other names:XELOX. |
| Sponsor | Hebei Medical University |
| Drug class | Platinum-based chemotherapy combination; antimetabolite |
| Target | DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that forms DNA adducts, leading to cell cycle arrest and apoptosis. Capecitabine is a prodrug of 5-fluorouracil that preferentially activates in tumor tissue, inhibiting thymidylate synthase and incorporating into RNA/DNA. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Gastric cancer
- Pancreatic cancer
- Breast cancer
Common side effects
- Neuropathy (peripheral sensory)
- Nausea and vomiting
- Diarrhea
- Neutropenia
- Anemia
- Hand-foot syndrome
- Fatigue
- Thrombocytopenia
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (NA)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) (PHASE1, PHASE2)
- Pan Tumor Rollover Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |